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identical in PDGF-BB-stimulated cells from MA and SV. How-
ever, apoptosis rates were higher in MA than SV determined 
by lactate dehydrogenase release, DNA fragmentation, and 
Hoechst 33258 staining. Moreover, caspase inhibitors (Z-
VAD-fmk, Boc-D-fmk) abrogated the different proliferation 
rates of VSMC from MA versus SV. Western blotting and 
GSK3-  kinase assay revealed lower Akt activity in VSMC 
from MA versus SV, while total Akt expression was identical. 
Adenoviral transduction of a constitutively active Akt mu-
tant abrogated the different proliferation rates of VSMC from 
MA versus SV.  Conclusions: Higher apoptosis rates due to 
lower Akt activity rather than different cell cycle regulation 
account for the lower proliferation of VSMC from MA as com-
pared to SV. VSMC apoptosis may protect MA from bypass 
graft disease. 
 Introduction 
 Coronary artery disease is often treated by bypass 
grafting. Internal mammary artery (MA) and saphenous 
vein (SV) are routinely used bypass grafts; patency rates 
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 Abstract 
 Background: The remarkable patency of internal mammary 
artery (MA) grafts compared to saphenous vein (SV) grafts 
has been related to different biological properties of the two 
blood vessels. We examined whether proliferation and 
apoptosis of vascular smooth muscle cells (VSMC) from hu-
man coronary artery bypass vessels differ according to pa-
tency rates.  Methods and Results: Proliferation rates to se-
rum or platelet-derived growth factor (PDGF)-BB were lower 
in VSMC from MA than SV. Surface expression of PDGF   -re-
ceptor was slightly lower, while that of   -receptor was slight-
ly higher in MA than SV. Cell cycle distribution, expression of 
cyclin E, cdk2, p21, p27, p57, and cdk2 kinase activity were 
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of MA grafts, however, are higher than those of SV  [1] . 
Vascular smooth muscle cells (VSMC) accumulate in the 
subendothelium of grafted vessels and lead to neointima 
formation; therefore, VSMC proliferation plays a major 
role in long-term patency  [2] . Interestingly, VSMC are a 
heterogeneous population; indeed, VSMC from different 
vascular beds exhibit different intrinsic properties  [3] . 
Hence, VSMC from MA and SV may differ in their in-
trinsic properties as well, thereby determining patency 
rates of grafted vessels. 
 Growth factors such as platelet-derived growth factor 
(PDGF) are released from aggregating platelets leading to 
stimulation of VSMC proliferation. As platelet adhesion 
to bypass grafts is initiated within minutes after grafting, 
VSMC of grafted vessels are exposed to PDGF from a very 
early time point on; not surprisingly, such growth factors 
are important regulators of neointima formation  [4] . 
However, the effect of growth factors on different bypass 
grafts may be modulated by intrinsic properties of the 
grafts, as VSMC from MA and SV may differ in these 
properties resulting in a differential response to growth 
factors. Moreover, not only proliferation, but also apop-
tosis of VSMC plays an important role in the pathogen-
esis of vascular diseases such as atherosclerosis and by-
pass graft disease  [5, 6] . Indeed, VSMC apoptosis may 
reduce neointima formation  [7] , and the balance of VSMC 
proliferation versus apoptosis may be a more important 
determinant of long-term patency of grafted vessels than 
either parameter alone. 
 Therefore, the present study was designed to analyze 
proliferation and apoptosis of VSMC from MA as com-
pared to SV. We observed that proliferation rates of VSMC 
from MA and SV are consistent with the different paten-
cy rates. Neither PDGF receptor expression nor cell cycle 
regulation could account for this difference; instead, dif-
ferent apoptosis rates due to different Akt activation were 
identified. 
 Methods 
 Cell Culture and Proliferation 
 VSMC and endothelial cells (EC) of MA, SV, and aorta were 
isolated from patients undergoing coronary artery bypass graft-
ing, which was approved by the Ethics Committee of Human Re-
search at the University Hospital. Cells were obtained from 32 
patients and 34 vessels (MA: 13 vessels from 13 patients; SV: 16 
vessels from 14 patients; aorta: 5 vessels from 5 patients). VSMC 
were isolated by explant generation, EC by the enzymatic method. 
The identity of each VSMC and EC isolate was confirmed by 
 immunofluorescent staining for smooth muscle   -actin (No. 
1148818, Roche Diagnostics, Mannheim, Germany) and uptake 
of acLDL (No. L3484, Molecular Probe, Leiden, The Netherlands), 
respectively. VSMC and EC were cultured as described. VSMC 
were used for experiments up to passage 12 and EC up to pas-
sage 5. To induce G0/G1 arrest, VSMC were kept in serum-free 
medium containing 0.1% BSA fraction V (Sigma, St. Louis, Mo., 
USA) for 48 h prior to stimulation with 10% FCS or 10 ng/ml hu-
man PDGF-BB (No. 220-BB, R&D Systems, Minneapolis, Minn., 
USA). Cell number was determined after 0, 2, 4, and 6 days using 
an improved Neubauer hemacytometer. G1/S-progression was 
evaluated by  3 H-thymidine incorporation; 20 h after mitogenic 
stimulation, VSMC were pulsed with  3 H-thymidine for 4 h, and 
incorporated  3 H-thymidine was detected by a   -counter (Beta-
matic V; Kontron Instruments, Milan, Italy)  [8] . This time win-
dow for  3 H-thymidine incorporation was chosen because prelim-
inary experiments revealed a progressive decline in the cellular 
level of the cyclin-dependent kinase inhibitor p27 over 30 h after 
mitogenic stimulation (data not shown); p27 expression is indeed 
known to be high in arrested cells and to decrease during G1-pro-
gression and S-phase entry.  
 Western Blot Analysis and Kinase Assays 
 Western blot analysis of cell cycle proteins was performed on 
whole-cell lysates as described  [9] . Membranes were incubated 
with antibodies against cyclin E (No. sc-198), cdk2 (No. sc-163), 
p27 Kip1  (No. sc-528; all from Santa Cruz Biotechnology, Santa 
Cruz, Calif., USA), p21 Cip1  (No. 65961A), p57 Kip2  (No. 556346; 
both from Pharmingen, San Diego, Calif., USA), Akt (No. 9272), 
p-Akt (No. 9271; both from Cell Signaling Technology, Beverly, 
Mass., USA) and acetylated tubulin (No. T-6793, Sigma). Immu-
noprecipitations for cdk2 kinase assays were performed as de-
scribed  [9] . Labeled proteins were resolved on 12% SDS-PAGE 
and subjected to autoradiography. Akt kinase activity was deter-
mined by GSK3-  phosphorylation according to the manufactur-
er’s recommendations (No. 9840, Cell Signaling Technology). 
 Flow Cytometry and Cell Death Assays 
 For analysis of PDGF receptor expression, VSMC were de-
tached with 2 m M EDTA (pH 8.0) in PBS, collected, and washed 
with PBS containing 20% FCS. Cells were stained with anti-PDGF 
receptor   (No. 556001, Pharmingen) or   antibody (No. 
MAB1263, R&D Systems) for 1 h on ice, and then incubated with 
rabbit anti-mouse IgG phycoerythrin-conjugated antibody (No. 
P9287, Sigma) for 1 h on ice. Cells were washed, fixed with 1% 
paraformaldehyde, and analyzed on a FACSCalibur cytometer 
using CellQuest software (Becton Dickinson, Franklin Lakes, 
N.J., USA).  
 For analysis of cell cycle distribution as well as quantification of 
fragmented DNA, cells were harvested, washed twice in PBS, fixed 
in 2% paraformaldehyde for 60 min, and permeabilized in 0.2% 
Tween-20. The cells were then treated with 1 U RNase in 1 ml PBS 
for 30 min at 37  °  C, resuspended in 0.03 mg/ml propidium iodide, 
and analyzed by flow cytometry  [10] . Cell death was also examined 
using a colorimetric assay for lactate dehydrogenase activity (Roche 
Diagnostics) according to the manufacturer’s instructions. Apop-
tosis was determined by staining trypsinized VSMC with 10   g/ml 
Hoechst 33258 (No. B1155, Sigma) for 5 min, which were then 
washed twice with PBS and 10% FCS, resuspended in 25   l PBS and 
transferred to a microscope slide. 300 cells were analyzed by fluo-
rescent microscopy, and the number of Hoechst-positive cells 
showing condensed chromatin was determined  [11] . 
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 Cells were growth arrested and then stimulated with 10 ng/ml 
PDGF-BB plus 50   M of the specific caspase inhibitor Z-VAD-
fmk (Bachem, Heidelberg, Germany) or 30   M of another spe-
cific caspase inhibitor Boc-D-fmk (No. 218745, Calbiochem, 
Darmstadt, Germany). Media were changed daily, and cell num-
ber was determined after 4 days of mitogenic stimulation. 
 Adenoviral Transduction 
 Cells were transduced with an adenoviral vector expressing a 
constitutively active Akt mutant (Ad-HA-m/p-PKB) or a control 
vector harboring the green fluorescent protein (GFP) at a multi-
plicity of infection of 800 pfu/cell. For some experiments, a mul-
tiplicity of infection of 100 pfu/cell was used. The vectors were 
kindly provided by Brian A. Hemmings, PhD (Friedrich Miescher 
Institute Basel, Switzerland) and Zhihong Yang, MD (University 
of Fribourg, Switzerland)  [12, 13] . Medium was then removed and 
cells were stimulated with proliferation medium. Increase in cell 
number was determined after 4 days of mitogenic stimulation.  
 Statistics 
 Values represent means  8 SD of 4–5 independent experi-
ments. For each experiment, VSMC from a different patient were 
used. Statistical evaluation was performed by unpaired Student’s 
t test or ANOVA as appropriate. A p value  ! 0.05 was considered 
to indicate a significant difference. 
 Results 
 Proliferation  
 Isolation of VSMC was successful in 56% of explants 
from MA and in 100% from SV, respectively ( table 1 ). 
This difference was related to both a lower number of ex-
plants with outgrowth and a slower growth in MA as 
compared to SV. Therefore, the proliferation pattern of 
VSMC isolates from MA and SV was examined. Cell 
number was determined every other day for up to 6 days. 
Proliferation of MA VSMC to 10% FCS was lower than 
that of SV (cell number on day 6: MA: 28,365  8 22,700 
and SV: 69,750  8 43,400; p  ! 0.01; n = 13–15;  table 1 ). A 
similar pattern was observed when VSMC from both ves-
sels were derived from the same patient (cell number on 
day 6: MA: 27,938  8 11,663, SV: 92,031  8 38,853; p  ! 
0.05; n = 4;  fig. 1 a). Thus, proliferation of VSMC from 
MA was lower than that of SV in response to FCS.  
 Table 1. Growth of VSMC and EC from human coronary artery 
bypass vessels in response to different stimuli 
Vessel MA SV p value
Explant outgrowth of 
VSMC, % 55.6 100
VSMC, n !1,000
PDGF (day 0) 13.285.1 15.685.4 NS
PDGF (day 2) 17.086.6 29.1812.7 <0.01
PDGF (day 4) 21.7811.9 45.6817.8 <0.005
PDGF (day 6) 28.4822.7 69.8843.4 <0.001
EC, n !1,000
VEGF (day 4) 6.480.6 6.681.8 NS
FGF (day 4) 3.780.2 4.581.0 NS
NS = Nonsignificant; VEGF = vascular endothelial growth 
factor; FGF = fibroblast growth factor.
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 Fig. 1. Increase in the VSMC number from MA ( $ ) and SV ( U ). 
Cells were serum starved for 48 h and then stimulated with a mi-
togen.  a Stimulation with 10% FCS.  b Stimulation with 10 ng/ml 
PDGF-BB.  a ,  b Cell numbers were lower in MA than SV (p  ! 0.05). 
 c Stimulation with 10 ng/ml PDGF-BB; G0/G1 phase arrest mea-
sured by  3 H-thymidine incorporation was lower in MA ( ) ) than 
SV ( $ ; p  ! 0.05). 
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 To study the effect of a specific mitogen, VSMC were 
stimulated with 10 ng/ml PDGF-BB. MA VSMC exhib-
ited only minimal proliferation, while the number of SV 
VSMC increased faster (cell number on day 6: MA: 
15,446  8 5,528 and SV: 33,094  8 5,244; p  ! 0.01; n = 4; 
 fig. 1 b). PDGF-BB-induced exit from G0/G1 phase was 
determined by  3 H-thymidine incorporation. Consistent 
with proliferation rates,  3 H-thymidine incorporation 
was lower in MA VSMC as compared to SV (MA: 149.6 
 8 69.8 and SV: 271.9  8 46.6; p  ! 0.05; n = 4;  fig. 1 c). 
Thus, the increase in the number of MA VSMC was low-
er than that of SV after stimulation with PDGF-BB. 
VSMC from MA were also compared to aorta. Again, 
MA VSMC exhibited only minimal proliferation in re-
sponse to 10 ng/ml PDGF-BB over 6 days, while the 
number of aorta VSMC increased faster (cell number on 
day 6: MA: 6,250  8 5,796 and aorta: 21,188  8 13,097; 
p  ! 0.05; n = 5). Thus, the lower increase in cell number 
was specific for MA rather than being a general prop-
erty of arterial vessels. 
 Receptor Expression 
 The different proliferation rates of VSMC from MA 
versus SV in response to PDGF-BB may be related to dif-
ferent expression of PDGF receptors. Therefore, surface 
expression of PDGF receptor   and   was determined by 
FACS analysis. Expression of receptor   was slightly 
higher in VSMC from MA than SV (MA: 100% and SV: 
80.6  8 10.5%; p  ! 0.01; n = 4;  fig. 2 a). PDGF receptor   
expression was slightly lower in VSMC from MA than SV 
(MA: 76.2  8 10.5% and SV: 100%; p  ! 0.005; n = 4; 
 fig. 2 a). Thus, the pattern of PDGF receptor expression 
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 Fig. 2. Cell cycle regulation of VSMC from MA and SV. Cells were serum starved for 48 h and then stimulated 
with PDGF-BB for 30 h.  a PDGF receptor expression analyzed by FACS.   expression was slightly higher in MA 
( ) ) than SV ( $ ; p  ! 0.01).   expression was slightly lower in MA ( ) ) than SV ( $ ; p  ! 0.005).  b Cell cycle dis-
tribution was determined by propidium iodide incorporation and analyzed by FACS. A similar distribution was 
observed between MA ( ) ) and SV ( $ ; p = nonsignificant).  c Cell-cycle-regulatory protein expression was de-
termined by Western blotting and observed to be similar between MA and SV.  d Cdk2 kinase activity was de-
termined by H1 kinase assay and observed to be similar between MA and SV. 
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did not account for the different proliferation rates of 
VSMC from MA and SV.  
 Cell Cycle Progression 
 The different proliferation rates of VSMC from MA 
versus SV may be due to differences in signal transduc-
tion or cell cycle regulation. In either case, differences in 
cell cycle progression would be expected. Therefore, cell 
cycle distribution and G1 progression was compared in 
VSMC from MA and SV. Preliminary experiments exam-
ining cell cycle protein expression at 0, 6, 12, 18, 24, and 
30 h of mitogenic stimulation revealed that differences in 
the expression of these proteins progressively develop in 
VSMC over the 30-hour observation period (data not 
shown); hence, the analysis was performed at 0 and 30 h. 
Propidium iodide incorporation demonstrated similar 
cell cycle distribution in VSMC from both vessels (% of 
cells in G0/G1 phase: MA: 79.5  8 10.0, SV: 74.25  8 8.7; 
S phase: MA: 5.25  8 1.5, SV: 9.5  8 5.5; G2/M phase: MA: 
11  8 5.0 and SV: 14  8 3.5; n = 4; p = nonsignificant; 
 fig. 2 b). Next, Western blot analysis for expression of cell 
cycle proteins regulating G1 progression was performed. 
Consistent with cell cycle distribution, VSMC from MA 
and SV exhibited an identical pattern of cell cycle protein 
expression ( fig. 2 c). Indeed, in VSMC from both vessels, 
cyclin E expression remained unaltered by PDGF stimu-
lation, the lower part of the cdk2 double band represent-
ing threonine-phosphorylated and hence activated cdk2 
was induced, the cyclin-dependent kinase inhibitor (CKI) 
p21 was slightly upregulated, p27 was downregulated, 
and p57 remained unchanged. Consistent with these ob-
servations, cdk2 kinase activity was identical in VSMC 
from MA and SV ( fig. 2 d). Thus, both cell cycle distribu-
tion and G1 progression were identical in VSMC from 
MA and SV, and therefore did not account for the differ-
ent proliferation rates. 
 Cell Death 
 As neither PDGF receptor expression nor cell cycle 
progression could account for the different proliferation 
rates of VSMC from MA and SV, cell viability after 30 h 
of PDGF-BB stimulation was examined. FACS analysis of 
fragmented DNA revealed a higher number of dead cells 
in MA as compared to SV (% dead cells: MA: 1.89  8 1.26 
and SV: 1.08  8 0.61; p = 0.20; n = 5;  fig. 3 a). Quantifica-
tion of cell death by lactate dehydrogenase activity con-
firmed this observation; indeed, cell death was higher in 
VSMC from MA as compared to SV (% of maximal re-
lease: MA: 31.12  8 14.38 and SV: 8.04  8 7.03; p  ! 0.02; 
n = 5;  fig. 3 b). To differentiate apoptosis from necrosis, 
VSMC were stained with Hoechst 33258, and the percent-
age of Hoechst-positive cells exhibiting condensed chro-
matin was determined. Consistent with the other death 
assays, apoptosis rates were higher in VSMC from MA 
than SV (MA: 3.04  8 0.99% and SV: 1.46  8 0.50; p  ! 
0.05; n = 4;  fig. 3 c). This pattern of cell death was consis-
tent with the different increase in VSMC number from 
MA and SV. 
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 Fig. 3. Different cell death rates of VSMC from MA ( ) ) and SV 
( $ ). Cells were serum starved for 48 h and then stimulated with 
PDGF-BB for 30 h.  a Fragmented DNA was analyzed by FACS and 
was higher in MA than SV (p = 0.20).  b Lactate dehydrogenase 
(LDH) release was determined by ELISA and was higher in MA 
than SV (p  ! 0.02).  c Hoechst-positive cells were identified by 
fluorescence microscopy; p  ! 0.05, MA vs. SV. 
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 Caspase Inhibition 
 As activation of caspases is a key element in apopto-
sis, VSMC were treated with specific caspase inhibitors. 
VSMC were stimulated with PDGF-BB over 4 days (in-
crease in cell number: MA: 5,781  8 4,280 and SV: 27,734 
 8 11,777; p  ! 0.01; n = 6). Addition of the caspase in-
hibitor Z-VAD-fmk abolished the difference in prolif-
eration of VSMC from MA versus SV, confirming that 
the different cell death rates are determined by apopto-
sis (increase in cell number in the presence of Z-VAD-
fmk: MA: 28,520  8 19,270 and SV: 36,953  8 17,888; 
p = nonsignificant; MA vs. MA+VAD: p  ! 0.05; SV vs. 
SV+VAD: p = nonsignificant; n = 6;  fig. 4 a). Another 
specific caspase inhibitor, Boc-D-fmk, had a similar ef-
fect (increase in cell number in the presence of Boc-D-
fmk: MA: 25,078  8 16,980 and SV: 29,688  8 11,570; 
p = nonsignificant; MA vs. MA+Boc: p  ! 0.05; SV vs. 
SV+Boc: p = nonsignificant; n = 6;  fig. 4 a). Thus, these 
data indicate that the different proliferation rates of 
VSMC from MA and SV are due to different caspase-
dependent apoptosis rates.  
 Akt Activity 
 Akt plays a key role in the cellular balance between 
proliferation and apoptosis. Therefore, levels of total and 
activated Akt were determined by Western blotting, 
which revealed similar expression, but lower activation in 
VSMC from MA than SV (n = 4;  fig. 4 b). These data were 
confirmed by an Akt activity assay determining the levels 
of phosphorylated GSK-3  ; MA VSMC exhibited a lower 
GSK-3  activation as compared to SV (n = 3;  fig. 4 b). 
Similar to the effect of caspase inhibitors, adenoviral 
transduction of the constitutively active Akt mutant Ad-
HA-m/p-PKB abrogated the growth differences in VSMC 
from MA and SV  [13] . The VSMC number was lower in 
MA than SV after PDGF stimulation (increase in cell 
number in %: MA: 0  8 13.19 and SV: 70.16  8 22.37; p  ! 
0.02). Transduction with the Akt mutant Ad-HA-m/p-
PKB revealed a similar VSMC number in MA and SV 
(increase in cell number in %: MA+AdPKB: 80.27  8 21.2 
and SV+AdPKB: 69.17  8 29.52; p = nonsignificant; MA 
vs. MA+AdPKB: p = 0.01; SV vs. SV+AdPKB: p = nonsig-
nificant). No effect of the control vector was observed 
(increase in cell number in %: MA+AdGFP: 11.87  8 17.20 
and SV+AdGFP: 68.42  8 24.57; p  ! 0.01; MA vs. 
MA+AdGFP and SV vs. SV+AdGFP: p = nonsignificant; 
n = 4;  fig. 4 c). To confirm the specificity of these data, the 
effect of transduction with Ad-HA-m/p-PKB on MA 
VSMC was also examined at a lower multiplicity of infec-
tion (100 pfu/cell). After transduction, the cell number 
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 Fig. 4. Caspase inhibitors abolish growth differences in VSMC 
from human MA and SV.  a VSMC from MA ( ) ) and SV ( $ ) were 
serum starved for 48 h and then stimulated with PDGF-BB plus 
either the capase inhibitor Z-VAD-fmk or Boc-D-fmk. Cell num-
ber was determined on day 4 after stimulation. Caspase inhibition 
enhanced cell number in MA (p  ! 0.05) but not SV (p = nonsig-
nificant).  b Akt activity of VSMC from MA and SV. Cells were 
lysed, levels of phosphorylated Akt were determined by Western 
blotting, and Akt activity was also measured by GSK3-  phos-
phorylation.  c VSMC from MA ( ) ) and SV ( $ ) were transduced 
with 800 pfu of an adenoviral vector expressing a constitutively 
active Akt mutant (Ad-HA-m/p-PKB) or control vector (Ad-GFP) 
and stimulated with PDGF-BB. Cell number was determined 4 
days after stimulation. Constitutively active Akt enhanced cell 
number in MA (p = 0.01) but not SV (p = nonsignificant). 
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was higher as compared to control conditions (Ad-PKB: 
16,625  8 2,604, Ad-GFP: 11,844  8 2,040 and control: 
10,312  8 2,632; p  ! 0.05 for Ad-PKB vs. Ad-GFP, p  ! 0.05 
for Ad-PKB vs. control, p = nonsignificant for Ad-GFP 
vs. control). These data demonstrate that different Akt 
activities determine the different apoptosis rates of VSMC 
from MA and SV.  
 Discussion 
 This study demonstrates that VSMC from MA and SV 
exhibit different intrinsic properties, indicating that there 
is an intrinsic heterogeneity of these vessels. Indeed, 
VSMC number increases slower in MA than SV, which is 
neither related to PDGF receptor expression nor PDGF-
BB-induced cell cycle progression, but is rather deter-
mined by higher apoptosis rates due to lower Akt activa-
tion. This observation is consistent with the different 
propensity of MA and SV bypass grafts to accelerated 
atherosclerosis. 
 The increase in MA VSMC number was lower in re-
sponse to both FCS and PDGF-BB. This observation is 
consistent with patency rates of the respective bypass 
grafts; indeed, patients with an MA graft have a lower 
long-term risk of death as compared to those with only 
SV grafts  [1] . Hence, this observation suggests that 
VSMC are important for the pathogenesis of bypass graft 
disease and influence long-term patency rates. The low-
er increase in VSMC number from MA as compared to 
aorta indicates that VSMC from different arteries exhib-
it different properties; moreover, these data support the 
interpretation that the lower proliferation of MA VSMC 
may protect this vessel from atherosclerosis. The differ-
ence between MA and SV as well as MA and aorta must 
be related to intrinsic cellular properties, as it was ob-
served in isolated VSMC. Interestingly, proliferation of 
EC from MA versus SV was identical in response to dif-
ferent mitogens, suggesting that this aspect of endothe-
lial function may play a less important role than the well-
documented differences in the release of vasoactive me-
diators such as nitric oxide; however, more insight into 
the regulation of endothelial proliferation in MA versus 
SV has to be gained before definitive conclusions regard-
ing its role in the pathogenesis of bypass graft disease can 
be drawn. 
 PDGF receptor   expression was slightly higher, while 
receptor   expression was slightly lower in VSMC from 
MA and SV. Thus, PDGF receptor expression cannot ac-
count for the difference in response to PDGF-BB; hence, 
the reason for the different proliferation rates must be 
located below the membrane level. As mitogenic signals 
are integrated in G1 phase, differences in signal trans-
duction or cell cycle regulation would be reflected in a 
different G1 progression. The latter is mediated by pro-
tein complexes consisting of a cyclin and a cyclin-depen-
dent kinase (cdk)  [14] . Indeed, cyclin E and cdk2 pro-
mote late G1 progression and S-phase entry. Endogenous 
protein inhibitors of cyclin-cdk complexes (CKI) can 
modulate cdk2 activity; the members of the p21 family 
of CKI inhibit cell cycle progression in such a potent 
manner that they have been used for reducing neointima 
formation in restenosis models  [15] . Therefore, regula-
tion of G1 progression in VSMC from MA versus SV was 
examined by assessing expression and activity of cyclin 
E, cdk2, p21, p27, and p57. No difference in cell cycle dis-
tribution nor expression and activity of cell-cycle-regu-
latory proteins was observed, indicating that cell cycle 
progression is similar in VSMC from both vessels. In a 
previous report, a lower degree of p27 downregulation by 
PDGF-BB was observed in MA as compared to SV  [16] . 
We were not able to confirm this observation; in all ex-
periments, there was a tendency towards a higher p27 
downregulation in MA as compared to SV. A transient 
downregulation of p27 in SV within the 30-hour window 
can be excluded, as preliminary experiments clearly 
demonstrated a continuously increasing downregula-
tion over 30 h. The difference to our observation is most 
probably related to the fact that the protein lysates of MA 
and SV were made from different patients in the previous 
paper, while they were from the same patient in our ex-
periments. 
 As demonstrated by different methods, cell death due 
to apoptosis rather than cell cycle progression determines 
the lower increase in VSMC numbers to both FCS and 
PDGF-BB in MA versus SV, which suggests that VSMC 
apoptosis is involved in the higher patency rates of MA 
than SV. A role for VSMC apoptosis in vascular diseases 
was recognized when the reaction to balloon dilatation 
was examined; the VSMC number in injured arteries 
does not necessarily increase in spite of high levels of pro-
liferative activity  [6] . Consistent with this observation, a 
higher rate of apoptosis may counteract the development 
of neointima formation in the MA as well. In line with 
this interpretation, the neointima of bypass grafts devel-
ops rapidly, and this response shows many properties 
similar to the response to balloon dilatation. In addition 
to neointima formation, the higher propensity towards 
apoptosis of VSMC from MA may reduce atherogenesis 
in this vessel, as the accelerated atherosclerosis of bypass 
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grafts occurs on top of the neointima formed in the graft-
ed vessels. Hence, VSMC apoptosis may indeed protect 
the MA from bypass graft disease. 
 VSMC apoptosis is also observed in atherosclerotic le-
sions from human coronary and peripheral arteries  [5–7, 
17] . The functional importance of VSMC apoptosis in 
atherosclerosis is, however, under some debate. Indeed, 
the vulnerability of atherosclerotic plaques may increase 
with VSMC apoptosis, as the fibrous cap of lipid-rich 
plaques may be destabilized through proinflammatory 
interactions of apoptotic VSMC with macrophages, lead-
ing to remodeling of the extracellular matrix  [5] . There-
fore, VSMC apoptosis may promote plaque rupture, and 
apoptosis in the vessel wall is considered to be a two-
edged sword depending on the stage of atherosclerosis 
 [17, 18] . VSMC apoptosis primarily reduces neointima 
formation in the MA, as the latter only rarely becomes 
atherosclerotic; hence, apoptosis seems to play a benefi-
cial role in this vessel. Indeed, later stages of plaque for-
mation are an exception in the MA, so that a potential 
role of apoptosis in the rupture of plaques may not be rel-
evant for this vessel. 
 Akt is an important signaling molecule, which plays a 
key role in cell survival. It is known to be activated in 
VSMC by various growth factors such as PDGF-BB  [19, 
20] ; indeed, Akt mediates anti-apoptotic effects after 
stimulation with PDGF-BB  [12] . Consistent with these 
observations, Akt activity was lower in VSMC from MA 
than SV, while expression was identical. Moreover, trans-
duction of a constitutively active Akt mutant abrogated 
the growth differences between VSMC from MA and SV, 
indicating that the PDGF-induced increase in cell num-
ber critically depends of Akt activity in MA versus SV, 
and suggesting that modulation of Akt activity may have 
a therapeutic potential. Apart from Akt activity, other 
differences in the properties of arterial versus venous 
VSMC may contribute to the lower incidence of bypass 
graft disease in MA versus SV as well. Indeed, venous 
VSMC are less differentiated and synthesize lower levels 
of the inhibitory proteoglycan, decorin, as compared to 
arterial cells  [21] . 
 The major limitation of this study consists in its in vi-
tro nature. Cultured VSMC may not be representative of 
the VSMC population in vivo, as the isolated cells may be 
a selection of those growing best on culture dishes or in 
response to a defined mitogen. In addition, the extracel-
lular matrix of the intact vessel may differ from that syn-
thesized by VSMC in culture and thereby modulate cel-
lular properties. Moreover, VSMC in vivo are subjected 
to pulsatile stretch and exposed to cardiovascular risk 
factors. Therefore, this study suggests an important dif-
ference in Akt activity of VSMC from MA versus SV, 
which should be confirmed in an in vivo model. 
 In summary, this study demonstrates that the balance 
between proliferation and apoptosis determines the re-
sponse of VSMC from MA versus SV to mitogenic stimu-
lation. The higher apoptosis rates in VSMC from MA in-
dicate that apoptosis of these cells may play a beneficial 
role in bypass graft disease by primarily reducing neo-
intima formation. Thereby, the lower Akt activity in 
VSMC from MA seems to play a major role, suggesting 
that modulation of Akt activity may have a therapeutic 
potential for bypass graft disease. 
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